Dexrazoxane offers protection against anthracycline-induced cardiotoxicity, making it essential for patients undergoing chemotherapy. In adult studies, it significantly reduced heart damage risk without compromising overall survival or tumor response rates, supported by moderate-quality evidence. In children, its benefits for cardiac outcomes were mixed, with some studies showing no differences and others suggesting potential advantages. However, pediatric use raises concerns about a higher risk of secondary malignant neoplasms. These findings stress the importance of individualized treatment, balancing the cardioprotective benefits with the potential risks, particularly in younger patients, where more research is needed.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Dexrazoxane 250 AMPULES by Swiss Remedies, consult with your doctor or healthcare professional.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Cochrane Database Syst Rev. (2022): Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database of Systematic Reviews.
Home
